Genscript

Company Overview

GenScript is a global biotech company offering life sciences products and services across four segments: Life-science services and products, biologics development services, industrial synthetic biology products, and cell therapy.

The company caters to the CRISPR technology market through the Life-science services and products segment. This segment provides reliable, high-quality reagent services, products, and instruments globally, offering custom solutions for gene therapy, cell therapy, antibody therapeutics, vaccines, and diagnostics. The segment covers early discovery to pre-clinical stages with platforms like DNA synthesis, protein expression, and CRISPR tools. It also has expanded into cGMP manufacturing of CRISPR sgRNA, HDR templates, and peptides.

The company operates in over 100 countries and regions, with legal entities established in the U.S., China, Hong Kong, Japan, Singapore, Netherlands, Ireland, the U.K., Korea, and Belgium.

Financial Highlights (FY 2024)

Company's Business Segments

• Life-science Services and Products : This  segment provides a broad range of offerings, such as customised DNA synthesis, oligo nucleotide synthesis, protein production, peptide synthesis, catalog equipment, antibody development, and consumables.
• Biologics Development Services : This segment offers an integrated end-to-end service offerings to enhance biologics development and manufacturing for biotech and biopharma partners.
• Industrial Synthetic Biology Products : This segment helps in developing industrial enzyme through non-pathogenic microbial strains built using genetic engineering.
• Cell Therapy : This segment discovers and develops advanced CAR-T therapies for the treatment of liquid and solid tumors.